about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Boehringer ax­es biosim­i­lar de­vel­op­ment out­side US; Macro­Gen­ics, Chi­na's Zai Labs join forces to de­vel­op I/O ...

7 years ago
News Briefing

Cat­a­lyst Phar­ma's LEMS drug Fir­dapse wins FDA nod, as reg­u­la­tors keep the ap­proval en­gine run­ning at record speed

7 years ago
Pharma

In­cyte hires Janssen ex­ec as CSO Hu­ber moves to Third Rock; Syn­thorx set terms for $100M IPO

7 years ago
News Briefing

Found­ed by for­mer Phar­mas­set, Idenix ex­ecs, hep B com­pa­ny An­tios nabs $25M Se­ries A

7 years ago
Financing

Bio­Haven hopes to soothe Chi­nese headaches with Shang­hai sub­sidiary

7 years ago
China

BeiGene inks $60M li­cens­ing, re­search pacts with Zymeworks; Mer­ck, Ab­b­Vie, Am­gen back neu­ro up­start

7 years ago
News Briefing

In the lat­est re­verse merg­er, Vi­en­na's Ar­sa­nis serves as ve­hi­cle for X4 Phar­ma's Nas­daq list­ing

7 years ago
Pharma

Trump pro­pos­al ta­pers Medicare pro­tec­tion for cer­tain drugs if drug­mak­ers don't tem­per pric­ing

7 years ago
Pharma

Af­ter falling off a cliff, Edge Ther­a­peu­tics pro­vides can­cer-fo­cused PDS Biotech a re­verse merg­er on­to Nas­daq

7 years ago
Pharma

In a land­mark first, Chi­nese sci­en­tist claims birth of ge­net­i­cal­ly mod­i­fied ba­bies — and all hell breaks loose

7 years ago
China

Roivant joins forces with Ko­re­a's iN­tRON Bio to fight su­per­bugs; Evotec inks deal to lever­age AI to de­vel­op drugs

7 years ago
News Briefing

No­var­tis banks on the promise of dig­i­tal ther­a­peu­tics in the man­age­ment of chron­ic dis­or­ders

7 years ago
Pharma

Eli Lil­ly vet takes helm at Brick­ell Biotech; Stem­line's El­zon­ris se­cures speedy EU re­view

7 years ago
News Briefing

Stal­ler­genes Greer's dust mite al­ler­gy drug clears piv­otal study, edges clos­er to ap­proval

7 years ago
R&D

Ger­many's Mer­ck forges JV with Thiel's Palan­tir to har­ness da­ta to at­tack can­cer

7 years ago
Financing

Leo Phar­ma lines up an op­tion to buy Bridge­Bio's Pelle­Pharm and its PhI­II rare skin can­cer drug

7 years ago
Pharma

Fortress Biotech sells bro­ker­age firm fol­low­ing Reuters ex­posé; Tra­con con­tends with an­oth­er set­back in brain can­cer

7 years ago
News Briefing

Tesaro stock soars on an­oth­er re­port the PARP play­er is ex­plor­ing a sale

7 years ago
Deals

Un­de­terred by ex­ec ex­o­dus, Im­muno­core nabs $100M cash to co-de­vel­op pre­clin­i­cal as­set with Roche

7 years ago
R&D
Discovery

Gen­fit plans US list­ing as NASH drug­mak­ers race to the fin­ish line

7 years ago
Financing

While con­tro­ver­sy over Brex­it reach­es full boil, a phar­ma trade group sees the up­side in a draft deal

7 years ago
R&D
Pharma

With ra­dio­ther­a­py en vogue, Bel­gian start­up nabs near­ly $42M in Se­ries A fund­ing

7 years ago
Financing
Startups

As­traZeneca’s big MYS­TIC tri­al ends a com­plete fail­ure as Imfinzi/treme­li­mum­ab com­bo flops on over­all sur­vival

7 years ago
R&D

Cen­trex­ion de­lays IPO; Ex­elix­is makes $40M as Cabome­tyx wins EU nod

7 years ago
News Briefing
First page Previous page 20212223242526 Next page Last page
A service from the Financial Times